Minimal residual disease in multiple myeloma: why, when, where
Dec 10, 2021 · Understand the role of MRD status in prognosis in multiple myeloma. Explore how to apply MRD testing in clinical practice and its limitations. CLINICAL CASE.
What is minimal residual disease (MRD)? - MD Anderson Cancer Center
Jul 15, 2020 · Minimal residual disease (MRD) is common in patients with blood cancers, such as leukemia, lymphoma and multiple myeloma. But what does this mean for patients and their …
Measurable residual disease (MRD) dynamics in multiple myeloma …
Aug 7, 2024 · Minimal residual disease (MRD) assessment is a known surrogate marker for survival in multiple myeloma (MM) and sustained MRD has become the new therapeutic …
Minimal Residual Disease-Adapted Therapy in Multiple Myeloma…
Multiple myeloma (MM) is a biologically heterogeneous malignancy with relatively uniform treatment paradigms. This review aims to assess the growing role of Minimal Residual …
IMWG on MRD Response & Assessment | Int Myeloma Fn
The revised IMWG criteria allow, in addition to the classic CRAB features, three myeloma-defining events (MDEs). The presence of at least one of these markers is considered sufficient for a …
Minimal Residual Disease in Multiple Myeloma: Past, Present, …
The assessment of responses is critical in patients diagnosed with multiple myeloma. Nowadays, one of the most informative parameters to discriminate responses to treatment and prognosis …
Apr 12, 2024 · MRD is a measure of the number of multiple myeloma cells in the patient’s bone marrow, and it is often used in patients with complete response (CR) to further quantify depth of...
MRD and Mass Spectrometry | International Myeloma Foundation
Explore this page to learn about testing for multiple myeloma including flow cytometry (NGF), next-generation sequencing (NGS), and minimal residual disease testing through mass …
Dynamic monitoring of myeloma minimal residual disease with …
Feb 24, 2023 · Minimal residual disease (MRD) assessment has been established as a prognostic indicator for multiple myeloma (MM) [1]. MRD-negativity correlates with longer progression …
Minimal residual disease response-adapted therapy in newly …
Sep 27, 2023 · We present the final analysis of the MASTER trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) therapy in patients with newly diagnosed …